Perrigo Offered up to €275 M for HRA Pharma Rare Diseases Business

 Proposed Divestment of Branded Prescription Pharma Business Further Supports Perrigo's Strategic Focus on Consumer Self-Care

Total Purchase Consideration of up to €275 Million, Consisting of €190 Million in Cash Upfront and up to €85 Million in Potential Earnouts; Based on 2023 Adjusted EBITDA of ~€20M, Total Consideration Would be Accretive to Perrigo's Current Enterprise Value-to-EBITDA Multiple

Expected Net Proceeds to be Redeployed for Debt Repayment

Expected Impact From this Proposed Divestment was Included in the Company's Previously Issued 2024 Outlook

https://www.prnewswire.com/news-releases/perrigo-receives-binding-offer-to-divest-its-hra-pharma-rare-diseases-business-for-up-to-275-million-302127347.html